Lidocaine Injectable Syringes Recalled for Sterilization Assurance Concerns
CAPS Inc. is recalling 9,517 lidocaine 2% injectable syringes distributed nationwide due to lack of sterilization validation data. No illnesses have been reported.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall with a serious sterilization hazard in an injectable drug product. No illnesses or injuries have been reported, supporting a High severity level per the rubric.
Plain-English summary
Central Admixture Pharmacy Services Inc. (CAPS) is recalling 9,517 syringes of lidocaine 2% injection (20 mg/mL in 5 mL syringes) distributed nationwide. The product is a prescription-only injectable anesthetic.
The recall was initiated due to lack of assurance of sterility. The manufacturer has not provided validation data for sanitization cycles used in manufacturing, meaning there is no documented evidence that the sterilization processes effectively eliminate potential microorganisms from the final product.
Affected lot numbers include 17-271076 through 17-273771 with expiration dates from July 2023 through September 2023. Healthcare facilities and pharmacies that received these syringes should discontinue use immediately and return the product to CAPS Inc. or contact the FDA with questions.
No illnesses or injuries have been reported in connection with this recall. However, sterility failure in injectable products could result in serious infections if contaminated units were used in patient care.
The recalled product
- Product
- lidocaine 2%, 100 mg /5 mL, (20 mg/mL), 5 mL Syringe, Rx only, CAPS, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-6006-1
- Manufacturer
- Central Admixture Pharmacy Services Inc
- Category
- Drug — Injectable anesthetic
- Hazard
- sterility-failure
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot: 17-271076
- Exp. 7/24/2023
- 17-271132
- 17-271165
- Exp. 7/25/2023
- 17-271230
- 17-271250
- Exp. 7/26/2023
- 17-271508
- Exp. 7/31/2023
- 17-271595
- 17-271604
- Exp. 8/1/2023
- 17-271658
- Exp. 8/2/2023
- 17-271764
- Exp. 8/3/2023
- 17-271826
- Exp. 8/6/2023
- 17-271972
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27